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The transcription factor 7-like 2 (TCF7L2) gene is part of the Wnt/β-catenin signaling pathway
and plays a critical role in cell development and growth regulation. TCF7L2 variants rs12255372
and rs7903146 have been associated with risk of Type 2 diabetes. Few epidemiological studies
have examined the association between TCF7L2 and breast cancer risk. We investigated the
associations between 25 TCF7L2 single nucleotide polymorphisms (SNPs) and breast cancer in
Hispanic and non-Hispanic white (NHW) women from the 4-Corner’s Breast Cancer Study, the
San Francisco Bay Area Breast Cancer Study, and the Mexico Breast Cancer Study. A total of
4,703 Hispanic (2,093 cases, 2,610 controls) and 3,031 NHW (1,431 cases, 1,600 controls) women
were included. Odds ratios (OR) and 95 % confidence intervals (CI) were calculated using logistic
regression to estimate the association between the TCF7L2 SNPs and breast cancer risk. We also
examined effect modification by self-reported ethnicity, genetic admixture, and diabetes history.
After adjusting for multiple comparisons, four TCF7L2 SNPs were significantly associated with
breast cancer overall: rs7903146 (ORTT 1.24; 95 % CI 1.03–1.49), rs3750805 (ORAT/TT 1.15; 95
% CI 1.03–1.28), rs7900150 (ORAA 1.23; 95 % 1.07–1.42), and rs1225404 (ORCC 0.82; 95 %
0.70–0.94). Among women with a history of diabetes, the TT genotype of rs3750804 increased
breast cancer risk (OR, 2.46; 95 % CI 1.28–4.73). However, there was no association among
women without a diabetes history (OR, 1.06; 95 % CI 0.85–1.32). We did not find significant
interactions by ethnicity or by genetic admixture. Findings support an association between
TCF7L2 and breast cancer and history of diabetes modifies this association for specific variants.
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Introduction
The transcription factor 7-like 2 (TCF7L2) gene codes for a high mobility group (HMG) box
transcription factor. Located on chromosome 10q, TCF7L2 is part of the Wnt/β-catenin
signaling pathway and plays a critical role in cell development and growth regulation [1].
TCF7L2 protein is involved in blood glucose homeostasis and gene variants rs12255372 and
rs7903146 are reported to be associated with risk for Type 2 diabetes [2–4]. The mechanism
for this association is uncertain; however, evidence indicates that the gene may regulate
glucagon-like peptide 1 (GLP-1) through the Wnt-signaling pathway [5]. TCF7L2 also
regulates transcription of the proglucagon gene in enteroendocrine cells. In vitro, the
proglucagon gene is responsible for the insulinotropic hormone GLP-1 [5]. The dominant
negative TCF7L2 variant is reported to repress proglucagon gene mRNA expression and
subsequent GLP-1 synthesis [5]. Although results are mixed, some suggest that the TCF7L2
gene may play a role in obesity [6, 7].
The TCF7L2 gene plays a role in the Wnt/β-catenin pathway, which is reported to be
associated with human carcinogenesis [8], and specifically with breast cancer [9, 10]. While,
mutations within the Wnt pathway are rare in breast cancer, there is evidence for hyperactive
signaling, especially in triple negative [estrogen receptor (ER), progesterone receptor (PR),
and HER2 negative] or basal-like breast cancers [11–14]. Few epidemiological studies have
investigated the association between TCF7L2 and breast cancer risk [15–17]. We
investigated the associations between 25 TCF7L2 single nucleotide polymorphisms (SNPs)
and breast cancer risk in Hispanic and non-Hispanic white (NHW) women. We also
evaluated potential interactions between menopausal status and obesity, and tested for effect
modification by ethnicity, genetic admixture, and history of Type 2 diabetes. In addition, we
examined associations by tumor ER and PR status.
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The Breast Cancer Health Disparities Study (BCHDS) is comprised of participants from
three population-based case–control studies: the 4-Corner’s Breast Cancer Study (4-CBCS),
the San Francisco Bay Area Breast Cancer Study (SFBCS), and the Mexico Breast Cancer
Study [18]. All participants signed informed written consent prior to participation; the study
was approved by the Institutional Review Board for Human Subjects at each institution.
The 4-CBCS consisted of NHW and Hispanic/Native American women aged 25–70 years
residing in Arizona, Colorado, New Mexico, and Utah at the time of diagnosis or selection.
Cases newly diagnosed with in situ or invasive breast cancer between October 1999 and
May 2004 were identified through the state-wide cancer registries [19]. A total of 852
Hispanic, 22 American Indian, and 1,683 NHW breast cancer cases completed an in-person
interview in English or Spanish on breast cancer risk factors and participated in the
measurement of height and weight. Controls under the age of 65 years were randomly
selected from commercial mailing lists in Arizona and Colorado and driver’s license lists in
New Mexico and Utah. Controls 65 years of age and older were randomly selected from the
Center for Medicare Services (CMS) lists in all four states. Controls were frequency
matched to cases on ethnicity and 5-year age distribution. A total of 913 Hispanic, 23
American Indian, and 1669 NHW controls completed the interview and body measurements.
DNA from blood samples was extracted for 1,850 cases (606 Hispanics, 1,244 NHWs) and
2,057 controls (728 Hispanics, 1,329 NHWs).
The Mexico Breast Cancer Study consisted of Hispanic women between 28 and 74 years of
age, living in one of three states, Monterrey, Veracruz and Mexico City, for the past 5 years
[20]. Cases newly diagnosed with in situ or invasive breast cancer between January 2004
and December 2007 were identified at 12 participating hospitals from three main health care
systems in Mexico. Using a probabilistic multi-stage design, controls were randomly
selected from the catchment areas of the participating hospitals. A total of 1,000 cases and
1,074 controls completed an in-person interview and body size measurements, and DNA
was extracted from 85 and 96 % respectively.
The San Francisco Bay Area Breast Cancer Study (SFBCS) included Hispanic and NHW
women between the ages of 35 and 79 years from the San Francisco Bay Area [21, 22].
Cases newly diagnosed with invasive breast cancer between April 1995 and April 2002 were
identified through the Greater Bay Area Cancer Registry, and controls were selected by
random-digit dialing (RDD) and frequency matched based on ethnicity and 5-year age
distribution of cases. A total of 1,715 cases and 2,108 controls completed an in-person
interview on breast cancer risk factors in English or Spanish and body size measurements.
DNA from blood or mouthwash samples was available for 1,105 cases (793 Hispanics, 312
NHWs) and 1,318 controls (998 Hispanics, 320 NHWs).
Data harmonization
Interview data were harmonized across the three studies [18]. The main variables for
harmonization were selected based on study hypotheses and the genetic pathways of interest.
The present analyses included body mass index (BMI, kg/m2) calculated as self-reported
weight during the referent year (or more distantly recalled weight if referent year weight was
not available or measured weight if neither were available) divided by measured height
squared, parity (number of live births and stillborn pregnancies), age at first live birth or still
birth, self-reported ethnicity in the U.S. studies (all women in Mexico were considered
Hispanic), and highest level of education. The referent year was defined as the calendar year
prior to diagnosis for cases and selection into the study for controls.
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DNA was extracted from either whole blood (n = 7,286) or mouthwash (n = 637) samples.
Whole genome amplification (WGA) was applied to the mouthwash-derived samples prior
to genotyping. A tagSNP approach was used to characterize variation across candidate
genes. TagSNPs were selected as follows: linkage disequilibrium (LD) blocks were defined
using a Caucasian LD map and an r2 = 0.8; minor allele frequency (MAF) >0.1; range =
−1,500 bps from the initiation codon to +1,500 bps from the termination codon; and 1 SNP/
LD bin. A total of 104 Ancestral Informative Markers (AIMs) were used to distinguish
European and Native American ancestry in the study population [18]. All markers were
genotyped using a multiplexed bead array assay format based on GoldenGate chemistry
(Illumina, San Diego, California). A genotyping call rate of 99.93 % was attained (99.65 %
for WGA samples). We included 132 internal replicates that were blinded representing 1.6
% of the sample set. The duplicate concordance rate was 99.996 % as determined by
193,297 matching genotypes among sample pairs [18].
In the current analysis, we examined 25 TCF7L2 polymorphisms: rs176632, rs290489,
rs1028629, rs1225404, rs2094405, rs3750804, rs3750805, rs3814570, rs3814572,
rs4918796, rs6585206, rs7081062, rs7085532, rs7094463, rs7900150, rs7903146,
rs7903424, rs7919185, rs10749127, rs10885399, rs10885410, rs11196174, rs11196199,
rs12255372, and rs17685538. Online supplement 1 describes the TCF7L2 polymorphisms in
detail, including the minor allele frequencies (MAF) and adjusted Hardy–Weinberg
equilibrium (HWE) p values. Online supplement 2 provides genotype and haplotype
frequencies by ethnicity and case–control status. Online supplement 3 describes the LD
between all 25 TCF7L2 polymorphisms by self-reported ethnicity.
Tumor characteristics
Information on ER and PR status was obtained from the cancer registries in New Mexico,
Utah, Colorado, Arizona, and California for 979 (68 %) NHW cases and 958 (75 %)
Hispanic cases. These data were not available for Mexico.
Statistical methods
STRUCTURE was used to compute individual ancestry for each study participant assuming
two founding populations [23, 24]. Descriptive statistics were calculated for all covariates
and t tests and Chi-square tests were used to compare groups. Associations of TCF7L2
polymorphisms with breast cancer risk were stratified by ethnicity, genetic ancestry, history
of diabetes, BMI by menopausal status, and ER/PR status. Haplotype analysis was
conducted using PROC haplotype in SAS, which uses the expectation–maximization (EM)
algorithm to estimate the maximum likelihoods of haplotype frequencies based on the
multilocus sample of the genotypes under the HWE assumption [25]. Using the linkage
equilibrium method for initialization of estimated haplotype frequencies, SAS outputs all the
haplotype combinations for each individual as probability scores based on their genotypes.
The following SNPs were determined to have close base pair positions and yielded signals
for strong crude associations with breast cancer risk: rs7081062, rs7903146, rs7900150, and
rs11196199. Triplicates were then constructed based on the combination of rs7081062,
rs7903146, and rs7900150 and for rs7903146, rs7900150, and rs11196199. Haplotype
probabilities were categorized into probability for each subject and were included in the
regression models [26]. Online supplement 2 describes these haplotype combinations and
their frequencies by case–control status and ethnicity. The homozygous wildtypes for each
polymorphism were used as the referent categories. Using co-dominant models, genotype
associations for all TCF7L2 SNPs were estimated as OR with 95 % CIs by unconditional
logistic regression with adjustments for age and study center. Based on initial assessment of
the co-dominant associations, dominant models and haplotypes were also examined.
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Potential confounders included BMI, menopausal status, history of diabetes, percentage of
genetic admixture, parity, oral contraceptive use, education, family history of breast cancer,
age at menarche, history of hormone therapy use, physical activity, calories consumed per
day, and smoking status (ever or never). These were included in multivariable models if
their univariate p values were ≤0.20 and if they produced a change in the point estimate for
the main effects of the TCF7L2 genotypes of ≥10 % [27]. Interactions between TCF7L2
variants with ethnicity, genetic ancestry, BMI by menopausal status, and history of diabetes
were assessed using the likelihood-ratio test comparing the model including an interaction
term with a reduced model without the term.
Women were classified as either pre-menopausal or post-menopausal based on self-reported
responses to questions on menstrual history. Women who reported menstruation during the
referent year were classified as pre-menopausal. The classification for post-menopausal
women was established by using criteria provided by each individual study. If women were
taking hormonal therapy (HT) and still having periods and were at or above the 95th
percentile of age for ethnicity of those who reported having a natural menopause among
their study site, they were classified as post-menopausal. This age was 58 for NHW and 56
for Hispanics in the 4-CBCS, age 54 in the Mexico Breast Cancer Study, and 55 for NHW
and 56 for Hispanics in the SFBCS.
Multinomial logistic regression models were constructed to evaluate the associations
between TCF7L2 genotypes/haplotypes and breast cancer risk by ER/PR status [28, 29].
Since the Mexico Breast Cancer Study did not have data on ER/PR status, those subjects
were excluded from the multinomial regression analyses.
Results were adjusted for multiple comparisons taking into account tagSNPs within the gene
using the step-down Bonferroni correction (i.e., Holm’s method) based on the effective
number of independent SNPs as determined using the SNP spectral decomposition method
proposed by Nyholt [30] and modified by Li and Ji [31]. The interaction p values, based on
1-df likelihood-ratio tests, were adjusted using the step-down Bonferroni correction or the
Holm’s test [32]. We considered an adjusted p value of 0.10 or less as potentially important
for main effects and a Holm’s p value of 0.15 or less for interactions. All data analyses were
performed using SAS version 9.3 (SAS Institute, Cary, NC).
Results
A total of 7,733 breast cancer cases and controls were included in these analyses: 61 % were
Hispanic and 39 % were NHW. More Hispanic cases were diagnosed with ER−/PR− tumors
than NHW (23.2 vs. 18.3 %). Hispanic cases were more likely to be obese (BMI ≥ 30 kg/
m2) than NHW cases (39.7 vs. 24.8 %), and also had a significantly higher prevalence of
Type 2 diabetes compared to NHW cases (16.6 vs. 7.2 %) (Table 1).
Of the 25 TCF7L2 SNPs and 14 haplotypes evaluated, four polymorphisms and one
haplotype were significantly associated with breast cancer risk (Table 2). Increased risk was
associated with the TT genotype of rs7903146 (OR, 1.24; 95 % CI 1.03–1.49; p = 0.0369,
padj = 0.0474), the dominant model of rs3750805 (AT/TT vs. AA) (OR, 1.15; 95 % CI 1.03–
1.28; p = 0.0098, padj = 0.0420) and the AA genotype of rs7900150 (OR, 1.23; 95 % 1.07–
1.42; p = 0.0139, padj = 0.0457). The CC genotype of rs1225404 was inversely associated
with breast cancer risk (OR, 0.82; 95 % CI 0.70–0.94; p = 0.0149, padj = 0.0457). Although
the association was of borderline significance, the TT genotype of rs12255372 was
positively associated (OR, 1.20; 95 % CI 0.99–1.46). There was no evidence for effect
modification or significant interaction after stratification by self-reported ethnicity and by
levels of genetic admixture (data not shown).
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When stratified on diabetes history, there was a positive association with the TT genotype of
rs3750804 in women with a history of diabetes (OR, 2.46; 95 % CI 1.28–4.73), but no
association among women without a history (OR, 1.06; 95 % CI 0.85–1.32) (pinteraction =
0.0043; padj = 0.0086). The dominant mode of inheritance for rs3814570 (CC vs. CT/TT)
was inversely associated with risk among women with a history of diabetes (OR, 0.76; 95 %
CI 0.58–0.99), while there was a small increased risk among women without diabetes
history (OR, 1.13; 95 % CI 1.02–1.26) (pinteraction = 0.0099; padj = 0.0099) (Table 3).
We also examined whether the association between breast cancer and TCF7L2 was modified
by BMI and menopausal status (data not shown). There was a significant three-way
interaction between rs17685538, BMI and menopausal status (p = 0.004). Although the p
values for interactions were not significant for rs7900150 and rs1028629, the AA genotype
of rs7900150 (OR, 1.93; 95 % CI 1.22–3.06) and the TT genotype of rs1028629 (OR, 3.15;
95 % CI 1.09–9.10) were associated with increased breast cancer risk among obese (BMI ≥
30 kg/m2) pre-menopausal women. The CC genotype of rs4918796 (OR, 1.92; 95 % CI
1.18–3.10) and 2 copies of the A-T-A haplotype from the SNP combination between
rs7081062, rs7903146, and rs7900150 (OR, 1.61; 95 % CI 1.05–2.47) were associated with
increased breast cancer risk among obese, post-menopausal women.
Table 4 shows associations of TCF7L2 SNPs/haplotypes with breast cancer risk by ER/PR
tumor phenotype. The TT genotype of rs7903143 (ptrend = 0.0798, padj = 0.2186) was
associated with an increased risk for ER−/PR− tumors (OR, 1.56; 95 % CI 1.07–2.27). The
following polymorphisms and haplotypes were also associated with ER−/PR− breast cancer
with OR ranging from 1.59 to 2.39: rs7900150 (ptrend = 0.0271; padj = 0.1014), rs10749127
(ptrend = 0.0057; padj = 0.0327), and haplotypes A-T-A and T-A-G from the SNP
combination between rs7081062, rs7903146, and rs7900150. Although their unadjusted p
values did not reach statistical significance, the TT genotype of rs3814570 (OR, 1.49; 95 %
CI 1.04–2.14) and the dominant model (CT/TT vs. CC) of rs3750804 (OR, 1.25; 95 % CI
1.01–1.54) were also associated with an increased risk for ER−/PR− breast cancer. The CC
genotype of rs4918796 (ptrend = 0.0068; padj = 0.0327) was associated with an increased risk
for ER−/PR+ tumors (OR, 4.78; 95 % CI 1.89–12.12) and ER+/PR+ tumors (OR, 1.62; 95
% CI 1.20–2.20) (Table 4).
Discussion
In this large sample of Hispanic and NHW women from the BCHDS, four polymorphisms,
including rs7903146, and one haplotype were significantly associated with breast cancer risk
after adjusting for multiple comparisons. Although we did not find significant interactions
with ethnicity or by genetic admixture, our data suggest that the associations of rs3750804
and rs3814570 with breast cancer risk may be modified by diabetes history. Some
associations may have been influenced by obesity and menopausal status also. Lastly, results
suggest that the associations of several TCF7L2 polymorphisms and two haplotypes may
differ by ER and PR status.
We evaluated the associations of the more-widely studied polymorphisms, rs7903146 and
rs12255372, as well as 23 other SNPs to better characterize associations across the gene.
Consistent with our findings, Naidu et al. reported that the T allele of rs12255372 (TT
genotype, OR, 1.574; 95 % CI 0.829–2.987); GT/TT, OR, 1.365; 95 % CI 0.989–1.883) was
not associated with risk of breast cancer. However, carriers of the rs7903146 T allele (OR,
1.316; 95 % CI 1.022–1.695) and CT/TT genotypes, (OR, 1.419; 95 % CI 1.027–1.960) had
an increased risk [17]. Burwinkel et al. [15] examined the association of rs12255372 with
familial breast cancer risk and reported that the T allele was significantly, positively
associated (OR, 1.19; 95 % CI 1.01–1.42, p = 0.04) [15]. In contrast, Goode et al. [16] found
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no overall association (OR, 1.04; 95 % CI 0.89–1.22) [16]. However, in sub-group analyses,
associations were observed in pre-menopausal women (OR, 1.46; 95 % CI 0.99–2.15; p =
0.06), and those with HER2 positive (OR, 1.48; 95 % CI 1.00–2.01; p = 0.05) or triple
negative (OR, 2.01; 95 % CI 1.10–3.67; p = 0.02) breast cancer [16]. Although our study
was unable to assess the association between TCF7L2 and HER2 positive or triple negative
breast cancers, given incomplete data on HER2 status, results suggests that several of the
polymorphisms and haplotypes were significantly associated with the ER−/PR− tumor
phenotype.
Specific variants of TCF7L2 have been reported to be associated with risk of diabetes [2, 4,
5]. Although the underlying mechanisms are unclear, studies suggest that the gene may
regulate glucagon-like peptide 1 (GLP-1) through the Wnt-signaling pathway [5]. The
association between diabetes and breast cancer risk has received increased attention in
epidemiological research, but findings are mixed [33–42]. Based on the TCF7L2 gene’s
influence on diabetes, and its potential to increase breast cancer risk, we tested for
interaction effects between women who had a history of diabetes and women who did not.
We did not find significant interaction effects for variants rs7903146 and rs12255372, the
two SNPs that have been implicated as the major TCF7L2 polymorphisms associated with
diabetes. However, we identified two other variants, rs3750804 and rs3814570, that could
further be explored for associations with diabetes and breast cancer risk.
The mechanism underlying the association between TCF7L2 and breast cancer has not been
established, although the Wnt/β-catenin pathway has been implicated [9, 10]. In normal
cells, the levels of free cytosolic β-catenin are maintained, due to their degradation by the
APC, AXIN and kinase GSK3β complex. This multicomponent complex phosphorylates β-
catenin on N-terminal residues and targets the protein for ubiquitination and proteolysis [10,
43]. However, stimulation of the Wnt-pathway with a ligand inhibits the activity of the
complex, and β-catenin is less phosphorylated and ubiquitinated, leading to an accumulation
of β-catenin in the cytosol and increased entry of β-catenin into the nucleus [10, 43]. Once
in the nucleus, β-catenin combines with transcription factors of the TCF/LEF1 family and
forms a complex that stimulates the expression of certain target genes, including cyclin D1
and c-myc [10]. Other target genes for TCF7L2 have been found for breast cancer including
osteopontin (OPN), monocyte chemotactic protein-1 (MCP-1/CCL2), and RAD6B. OPN
functions in neoplastic transformation, malignant cell attachment, and migration and high
serum levels of OPN have been found to be associated with metastasis [1].
Continuous stimulation of the Wnt-signaling pathway leads to APC mutations that result in
increased expression of the β-catenin protein and higher β-catenin-Tcf transcriptional
activity. Some have investigated the role of mutations in the β-catenin, APC, and/or AXIN
in breast cancer carcinogenesis, but few have reported significant results. The best evidence
implicates mutations in APC [9]. It is not clear if the mutations in the Wnt-signaling
pathway components directly contribute to the β-catenin levels, as increased levels of β-
catenin-Tcf transcriptional activity have been found in breast cancer cell lines [9].
Our study has several strengths. It included a large sample size of over 3,500 cases and
4,200 controls from three population-based case–control studies conducted in the United
States and Mexico, and 1,937 cases with available data on tumor hormone receptor status.
Another important strength was the large number of Hispanic women included in the
analyses. Previous studies with TCF7L2 and breast cancer did not include Hispanic women
[15–17]. In addition to evaluating ethnic differences in associations between Hispanics and
NHWs, we were able to account for genetic admixture in our analyses. We previously
demonstrated that women with more Native American versus more European ancestry have
lower risk of breast cancer [18, 44]. Adjusting for genetic ancestry within admixed
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populations may also adjust for other underlying genetic factors that influence breast cancer
risk.
While we accounted for multiple comparisons, this adjustment does not completely
eliminate false positive associations. Therefore, replication of these results, particularly the
interaction effects by diabetes history, is needed. Another limitation is the lack of tumor
phenotype data for the Mexico Breast Cancer Study, which contributed 816 Hispanic cases
and 994 Hispanic controls. Hispanic women with breast cancer are more likely to have ER−/
PR− tumors [45], and inclusion of these women in our multinomial logistic regression
analysis might have strengthened our results by tumor phenotype.
In summary, using a tagSNP approach, our results suggest that there is a significant
association between the TCF7L2 gene and risk of breast cancer regardless of ethnicity and/
or Native American ancestry. A novel finding is potential effect modification by history of
diabetes for TCF7L2 polymorphisms rs3750804 and rs3814570. We also identified several
variants that may be associated with risk for the ER−/PR− tumor phenotype. Although we
did not find significant interactions by Hispanic ethnicity or by genetic admixture, additional
research is needed to elucidate factors that contribute to racial/ethnic disparities in breast
cancer. Future research on breast cancer genetics should involve identifying genetic
differences by race and ethnicity for breast cancer risk, prognosis, and survival. Such
findings could illuminate new pathways for breast cancer treatment.
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